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1.) To evaluate the performance characteristics of the Versant ® HBV DNA 3.0 assay (bDNA)+ (Versant, Bayer 
Healthcare LLC, Tarrytown, NY).  2.) To compare the Versant assay to the COBAS HBV TaqMan Analyte Specific 
Reagent assay (TaqMan) (Roche Molecular Systems, Pleasanton, CA) using random and defined patient populations.
Methods: Linearity and reproducibility were evaluated using 8 serial dilutions of 2 high titer HBV DNA patient samples 
tested in replicate.  Accuracy of the Versant and TaqMan assays was assessed by 5 serial dilutions of World Health 
Organization (WHO) HBV DNA international standard (96/746 I).  Correlation between Versant and TaqMan was 
assessed using Deming regression analysis on 3 groups of HBV DNA positive samples with HBV DNA titers ranging 
from 200 to >100,000,000 HBV DNA copies/mL: 168 random HBV DNA positive samples, 100 HBe antigen (Ag)-
/HBe antibody (Ab)+ HBV DNA positive samples, and 100 HBeAg+/HBeAb- HBV DNA positive samples.  All samples 
used in the evaluation were deidentified.     
Results:  The relationship of the Versant assay to expected concentration of serially diluted high-titer samples was: log 
observed = (0.983 × log expected) + 0.0054.  Within-run percent coefficient of variance (CV) ranged from 0.06% to 
2.40% at 5.62 and 4.16 log HBV DNA copies/mL, respectively.  Between-run percent CV ranged from 0.35% to 1.46% 
at 7.96 and 4.20 log HBV DNA copies/mL respectively.  Both the Versant and TaqMan assays provided accurate 
estimation of HBV DNA copies/mL concentration of the WHO International Standard (96/746 I).  Observed vs. 
expected equations for Versant were: observed = 1.07 expected – 0.39, R2 = 0.996, and for TaqMan: observed = 1.10 
expected – 0.47, R2 = 0.995.  Correlation studies demonstrated significant non-agreement between the Versant and 
TaqMan assays.  Deming regression equations were as follows: for the randomly selected positive samples, y = 0.915x + 
0.840 (R2 = 0.944, Standard Error of Estimates (SEE) = 0.485), for the 100 HBe Ag+/ HBe Ab – samples, y = 0.927x + 
0.796, (R2 = 0.836, SEE = 0.644), and for the 98 HBeAg-/ HBeAb+ samples y = 1.104x-0.405, (R2 = 0.935, SEE = 
0.374).   
Conclusion:  The Versant assay performs well with respect to within-run and between-run precision, and displays 
excellent linearity between the range of 2,000 to 100,000,000 HBV DNA copies/mL.  WHO International standard 
(96/746 I) dilutions indicated that both assays were accurate with respect to the international standard.  All clinical 
correlations displayed inconsistent bias between the assays.  Clinical sample comparisons and large SEEs indicate that 
results from the 2 assays would not be interchangeable for a given clinical sample. 
One vial of the WHO international standard for HBV DNA (97/746) was reconstituted as recommended, and 
serially diluted in HBV DNA negative normal human plasma (NHP) through 5 levels (1:4, 1:8, 1:40, 1:400, and 
1:800).  Each dilution was tested in duplicate in both the TaqMan and Versant assays.  Observed vs. expected 
results were determined for each assay using HBV DNA copies/mL.  The dashed line represents unity.      
Two (2) high-titer HBV DNA samples were diluted through 8 dilutions covering the range of the Versant assay.  
Each dilution member was run in triplicate on each of 4 separate Versant runs.  Observed vs. expected titers 
were calculated using a dilution in the middle of the range of the assay with the lowest CV to back calculate the 
titers of the remaining dilutions.  Expected concentration ranged from 3,116 to 135 million HBV DNA 
copies/mL. Seven (7) replicates of the highest titer dilutions in one sample, and four (4) of the lowest titer 
dilutions in the second sample were unable to be quantitated because the results were greater than and less than 
the analytical measurement range (AMR) of the assay, respectively.  Error bars represent one standard deviation 
of all results determined across all runs, and the black dashed line represents unity.
Two (2) high-titer HBV DNA samples were diluted through 8 dilution levels covering the range of the Versant assay.  Each dilution member was run in triplicate on each of 4 
separate Versant runs.  Within-run precision ranged from 0.06% at 5.62 log HBV DNA copies/mL to 2.40% at 4.16 log HBV DNA copies/mL.  Between-run precision ranged 
from 0.35% at 7.96 log HBV DNA copies/mL to 1.46% at 4.20 log HBV DNA copies/mL.  Between sample standard deviation was 0.068 (15.7% CV), between-run standard 
deviation was 0.018 logs (4.1% CV), within-run standard deviation was 0.062 logs (14.3% CV), and total run-to-run standard deviation was 0.064 logs (14.9% CV).  
One vial of the WHO international standard for HBV DNA (97/746) was reconstituted as recommended, and serially 
diluted in HBV DNA negative normal human plasma (NHP) through 5 levels (1:4, 1:8, 1:40, 1:400, and 1:800 
dilutions).  Each dilution was tested in duplicate in both the TaqMan and Versant assays.  Log HBV DNA copies/mL for 
each assay are plotted for a given dilution.  The Deming regression Versant and TaqMan HBV DNA copies/mL is: y = 
0.9762x + 0.1211, R
2
 = 0.9964, n = 10, SEE = 0.066.  The dashed line represents unity.      
+CE- Marked in Europe 
	 Quantitative HBV DNA measurements not only play a critical role in the management of patients undergoing anti-viral 
therapy, but they also contribute to the prognostics of HBV infection.  Recent treatment guidelines refer to specific HBV DNA 
threshold levels for initiation of therapy, although these levels have been chosen somewhat arbitrarily (1). Baseline HBV DNA 
levels are used as prognostic indicators prior to treatment initiation in the chronically infected patient and in those with 
hepatocellular carcinoma secondary to HBV infection (2).  Decreases in HBV DNA concentration are used to assess treatment 
efficacy in both chronically infected HBV patients (3, 4) and in those with recurrent HBV infection post transplant (5, 6). 
            The unique aspects of HBV biology and lack of standardization among HBV DNA assays have made HBV 
quantification challenging.  HBV has a large potential range of viral concentrations (7), and tests used to quantify HBV DNA 
require an analytical measurement range (AMR) of 7 logs or greater. Active HBV replication is frequently marked by the 
presence of HBV e antigen (HBeAg) while the presence of anti-HBe and the loss of HBeAg are surrogate markers for 
resolution of HBV infection.  Patients who are positive for HBeAg have, on average, higher HBV DNA titers than those 
without the antigen.  However, many HBV infected patients do not have HBeAg, are anti-HBe positive, and have mutations in 
the core and precore regions. These mutations may impact quantitative HBV DNA tests such as the COBAS HCV Monitor and 
COBAS TaqMan ASR assays whose primers are targeted to these regions, leading to incorrect quantification of HBV DNA. 
Finally, the lack of standardization between assays has made it difficult for physicians to use results from different methods 
interchangeably.  The introduction of the World Health Organization (WHO) international standard for HBV DNA (97/746) (8) 
allows for increased standardization of quantitative HBV DNA assays, similar to that now available for HCV RNA (9). 
Unfortunately, manufacturers and laboratories have been slow to adopt the WHO HBV DNA standard, which offers the 
potential for increased concordance between disparate quantitative HBV DNA methodologies. To meet clinical needs 
quantitative HBV DNA assays should have a large AMR, be insensitive to mutations in HBV DNA, and be standardized to 
WHO reference material. 
	 We have evaluated some of the critical performance characteristics of the Versant HBV DNA 3.0 assay (bDNA) (Versant) 
and COBAS HBV TaqMan ASR (TaqMan) assays.  We have evaluated the linearity and precision of the Versant assay using 
replicates of diluted clinical samples.  We have also assessed the concordance of the TaqMan and Versant assays in HBeAg 
positive (anti-HBe Negative), HBeAg negative (anti-HBe positive), and random patient samples.  We have further compared the 
performance of the TaqMan and Versant assays with respect to the WHO standard for HBV DNA (97/746).    
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Within Run Precision  
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Versant and TaqMan 
WHO International Standard
Observed vs Expected Log HBV DNA Copies/mL
TaqMan
y = 1.0976x - 0.4716
R2 = 0.9948
Versant 3.0
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Samples used in this study were clinical samples submitted to ARUP for HBV DNA testing by the COBAS HBV TaqMan ASR 
(TaqMan) testing and were de-identified prior to testing in this study.   The Institutional Review Board at the University of Utah 
approved the use of samples for the purpose of this study.
COBAS HBV TaqMan Analyte Specific Reagent (ASR) Assay
Calibration:
A single high titer HBV DNA containing sample was serially diluted in normal human serum (NHS) to create 8 calibrators.  Each 
calibrator was run in 8 replicates concurrently with 4 replicates of the WHO HBV international standard diluted 1:4 in the COBAS 
HBV TaqMan ASR (TaqMan) assay using the Qiagen BioRobot 9604 with the QIAamp 96 Virus kit and Qiagen biorobot 9604 for 
sample preparation and loading of K-tubes. Two-hundred uL of patient sample were processed using the QIAamp virus kit following 
the manufacturer’s guidelines, with a calium chloride buffer used to reconstitute the Qiagen protease instead of protease solvent and 
used at ½ the normal volume (5.1mL).  Samples were amplified in the COBAS TaqMan Analyzer using the cycling conditions given in 
the HBV TaqMan ASR master mix Technical Bulletin.  Results were normalized to HBV WHO standard and IU to copy ratio was 
previously determined to be 1:5.  Calibration coefficients were calculated using Roche ASR External Calibration Software Version 2.0 
and copy/mL values.  The calibration coefficients are considered valid for a single lot of reagents only.  
Versant HBV DNA 3.0 assay (bDNA) 
+




One vial of the WHO international standard for HBV DNA (97/746) was reconstituted as recommended and serially diluted in HBV 
DNA negative normal human plasma (NHP) through 5 levels (1:4, 1:8, 1:40, 1:400, and 1:800 dilutions).  Each dilution was tested in 
duplicate in both the TaqMan and Versant assays.  Observed vs. expected was determined for each assay and plotted.  Correlation of 
results between assays was determined through Deming Regression analysis.    
Linearity/ Reproducibility:
Two (2) high-titer HBV DNA samples were diluted through 8 dilution levels covering the range of the Versant assay.  Each dilution 
member was run in triplicate over 4 separate Versant runs. 
Within-run and Between-run precision:
Data from the linearity study was used to estimate the within run precision of the Versant assay
Clinical Correlation:
One-hundred eighty-four (184) samples previously tested by TaqMan and spanning the range of the TaqMan assay were selected and 
tested in Versant assay.  Log HBV DNA copies/mL results were compared between assays using Deming Regression analysis.   
Samples with results greater than the upper limit of the Versant assay were diluted and retested.
Prospective Clinical Correlation:
Samples with HBeAg, HBeAb and TaqMan HBV DNA status known were collected and tested in the Versant assay.  HBV DNA levels 
in the TaqMan and Versant assays were compared using 100 patient samples with the following serology status:
1.)	HBeAg positive & HBeAb negative (100 Samples)
2.)	HBeAg negative & HBeAb positive (100 Samples)
Log HBV DNA copies were compared using Deming Regression analysis.  Samples with results greater than the upper limits of 
quantiation in either assay were diluted and re-tested.  Overall bias between Versant and TaqMan was evaluated using the paired 
Student T statistic 
One-hundred sixty-eight (168) samples previously tested by TaqMan and spanning the range of the TaqMan assay (200 to 
1,000,000,000 HBV DNA copies/mL) were selected and tested in Versant assay.  Log HBV DNA copies/mL results were 
compared between assays using Deming Regression analysis.   Thirty-nine (39) samples with results greater than the upper 
limit of the Versant assay required dilution to achieve quantitative results.  Eighteen (18) samples tested in TaqMan required 
dilution to obtain quantitative results.  Twenty-seven (27) samples with quantitative results in TaqMan (range: 212 to 5,270 
copies/mL) were undetectable in Versant.  The Deming regression is: y = 0.915x + 0.840 R
2
 = 0.944, n = 141, SEE = 0.485.  A 
slope that was significantly different from 1.0 indicated non-linearity between assays.  Versant and TaqMan showed 
statistically significant non-linearity of quantitation with respect to each other. The black dashed line represents unity.  
HBeAg negative & HBeAb positive Clinical Sample Correlation
One-hundred (100) samples submitted to ARUP for HBV DNA, HBeAg, and HBeAb testing were selected 
(TaqMan quantitation range: 1,860 to 176 million copies/mL) and tested in the Versant assay.  Two samples 
returned results of <2,000 HBV DNA copies/mL (TaqMan quantitation: 2,390 and 2,540 copies/mL) and 2 
samples required dilution to obtain quantitative results in the Versant assay.  Deming regression is y = 1.1039x - 
0.405, R
2 = 0.9345, n = 98, SEE = 0.374.  Versant and TaqMan showed statistically significant non-linearity with 
respect to each other.  The black dashed line represents unity. 
HBeAg positive & HBeAb negative Clinical Sample Correlation
One-hundred (100) samples submitted to ARUP for HBV DNA, HBeAg, and HBeAb testing were selected 
(TaqMan results ranged from 1,340 to 4.5 billion HBV DNA copies/mL) and tested in the Versant assay.  
Thirteen (13) samples required dilution to obtain quantitative results in both the Versant and TaqMan assays.  
Deming regression is y = 0.927x + 0.796, R
2
 = 0.8355, n = 100, SEE = 0.644. Versant and TaqMan showed 
statistically significant non-linearity with respect to each other.  Versant results were on average 0.419 logs 
higher than TaqMan. However due to non-linearity between assays, bias was not constant across the quantitation 
range. The black dashed line represents unity. 
The Versant and TaqMan assays perform linearly with respect to the WHO international standard for 
HBV DNA (97/746) and are highly correlated between methods. 
The Versant assay is linear from 2,000 to 100,000,000 HBV DNA copies/mL.  The TaqMan assay 
appears to be more sensitive than the Versant assay and has a greater AMR
The Versant assay displays excellent within and between run precision
Variation between samples tested in TaqMan and Versant indicate that the same assay should be used to 
monitor patients being considered for or undergoing therapy for HBV infection.
Correlation Studies with HBeAg Negative Samples 
Correlation Studies with WHO International Standard
Correlation Studies with HBeAg Positive Samples 
Versant  vs TaqMan
Versant  vs TaqMan
Versant  vs TaqMan
Correlation studies demonstrated significant non-agreement  between the bDNA and TaqMan assays
